Trial Profile
A Phase II, Open-label, Efficacy and Safety Study to Evaluate the Effects of Mogroside Sweetener "PureLo" on Viral Load in Treatment Naïve, Genotype 1 Subjects With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Siraitia grosvenorii (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Canopus BioPharma
- 20 Nov 2008 New trial record.